Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is a single institution Phase II study for patients with unresectable Stage IIIA and
IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and
carboplatin followed by concurrent chemotherapy with radiation. The chemoradiation included
using paclitaxel and carboplatin with daily thoracic radiation to a total dose of 74 Gy.
Response rate was determined following the chemotherapy with gemcitabine and carboplatin and
evaluated again after the chemoradiation. Treatment toxicities were also assessed.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute